Cancer cells exploit fundamental cellular stress mechanisms to survive chemotherapy, potentially explaining why many colorectal cancer patients develop treatment resistance over time. This discovery reveals how tumor cells hijack normal protective pathways to become virtually impervious to standard drugs.
The mechanism centers on S-glutathionylation, a cellular response typically triggered during oxidative stress. When this pathway activates the enzyme METTL16, it initiates a cascade of RNA modifications that ultimately suppress CFTR protein expression. CFTR normally facilitates drug uptake into cells, so its suppression creates a molecular shield against chemotherapy agents. The process involves m6A methylation of IGF2BP3 RNA, demonstrating how epigenetic modifications can rapidly alter cancer cell vulnerability without changing underlying DNA.
This finding illuminates a critical blind spot in cancer treatment strategies. Most chemotherapy protocols assume consistent drug penetration across tumor cells, but this research suggests that cellular stress responses can dynamically alter therapeutic effectiveness. The METTL16-IGF2BP3-CFTR axis represents a potentially druggable pathway, offering new targets for combination therapies. However, the complexity of this multi-step process presents significant challenges for therapeutic intervention. The research is particularly relevant for colorectal cancer, where chemoresistance remains a primary cause of treatment failure and mortality. Understanding how oxidative stress pathways contribute to drug resistance may inform timing of treatments and development of resistance-reversing agents, though translating these molecular insights into clinical practice will require extensive validation studies.